文献速递免疫规划慢病防控与筛查

血液恶性肿瘤和实体瘤患者中常规推荐年龄范围外接种13价肺炎球菌结合疫苗的免疫原性与安全性

Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors.
PubMed 文献 · Vaccine · 2022-02-04

本研究在37例血液恶性肿瘤和实体瘤患者中评估推荐年龄范围外接种PCV13的免疫原性与安全性。接种后1个月针对所测6种血清型(除3型外)的Pn-IgG显著升高并维持保护水平至6个月,Pn-OPA针对全部6种血清型均显著升高并持续,未观察到严重不良事件。

要点

  • 推荐年龄范围外血液恶性肿瘤和实体瘤患者接种PCV13后1个月Pn-IgG显著升高,除3型外维持保护水平至6个月。
  • 针对全部6种所测血清型的Pn-OPA在接种后显著升高并持续。
  • 接种后1个月内未观察到严重不良事件。

核心结论

  • PCV13在推荐年龄范围外的血液恶性肿瘤和实体瘤患者中安全且具有免疫原性,包括针对3型。

研究设计与样本

  • 研究测量了推荐年龄范围外血液恶性肿瘤和实体瘤患者接种PCV13首剂前及接种后1个月和6个月针对PCV13血清型(1、3、5、6A、7F和19A)的肺炎球菌血清型特异性IgG(Pn-IgG)和调理吞噬活性(Pn-OPA)。
  • 从部分研究样本中测量了针对3型的肺炎球菌血清型特异性记忆B细胞(Pn-MBC)。
  • 37例患者完成研究,其中年轻患者组30例,成人患者组7例。

主要发现

  • 接种后1个月Pn-IgG显著升高,除3型外针对所测6种血清型中的5种维持保护水平至首剂接种后6个月。
  • 针对全部6种所测血清型,Pn-OPA均显著升高并持续。
  • 10例患者测量了Pn-MBC,其中90%至少检测到一种可检测的Pn-MBC,70%显示针对3型的Pn-MBC频率增加。
  • 接种后1个月内未观察到严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematological malignancy and solid tumor are major risks for invasive pneumococcal disease. Thirteen-valent pneumococcal conjugate vaccine (PCV13) is recommended for immunocompromised patients aged 6 years and older and adults who had not received the vaccine previously. However, vaccination for these individuals is not publicly subsidized in Japan. We measured pneumococcal serotype-specific IgGs (Pn-IgGs) and opsonophagocytic activities (Pn-OPAs) against PCV13 serotypes (1, 3, 5, 6A, 7F, and 19A) in patients with hematological malignancies and solid tumors who were outside the recommended age range for routine vaccination at baseline and at 1 and 6 months after the first dose of PCV13. Pneumococcal serotype-specific memory B cells (Pn-MBCs) against serotype 3 were measured from a portion of the study samples. Thirty-seven patients (30 in the young patient group and 7 in the adult patient group) completed the study. Pn-IgGs were significantly elevated at 1 month post-vaccination and persisted in protection level for 6 months after the first vaccination against all six serotypes measured except serotype 3. Pn-OPAs were significantly elevated and persisted as well against all six serotypes. Pn-MBCs were measured in 10 patients, and 90% of them had at least one detectable Pn-MBC, and 70% of them showed an increased frequency of Pn-MBCs against serotype 3. No serious adverse events were observed up to 1 month after vaccination. PCV13 is thus safe and immunogenic, including against serotype 3, in patients with hematological malignancies and solid tumors outside the recommended age range for routine vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Takeshita K, Ishiwada N, Takeuchi N, et al. Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors. Vaccine. 2022. PMID: 35125220. doi:10.1016/j.vaccine.2022.01.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。